Resistin impairs endothelium-dependent dilation to bradykinin, but not acetylcholine, in the coronary circulation

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 291, Issue 6, 2006, Pages

  Dick, Gregory M ^a,b   Katz, Paige S ^a   Farias III, Martin ^a   Morris, Michael ^a   James, Jeremy ^a   Knudson, Jarrod D ^a   Tune, Johnathan D ^a,b  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adipokine; Hormone; Obesity; Reactive oxygen species

Indexed keywords

ACETYLCHOLINE; ADIPOCYTOKINE; BRADYKININ; HYDROETHIDINE; INDOMETACIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PROSTAGLANDIN; RESISTIN; TEMPOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL TONE; CELL FUNCTION; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DOG; ENDOTHELIUM; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VASODILATATION;

ACETYLCHOLINE; ANIMALS; ANTIOXIDANTS; BRADYKININ; CORONARY CIRCULATION; CORONARY VESSELS; CYCLIC N-OXIDES; CYCLOOXYGENASE INHIBITORS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; EPOPROSTENOL; INDOMETHACIN; MALE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; REGIONAL BLOOD FLOW; RESISTIN; SPIN LABELS; SUPEROXIDES; VASODILATION; VASODILATOR AGENTS;

EID: 33845399034     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01035.2005     Document Type: Article

References (22)

1. Alexander JK. Obesity and coronary heart disease. Am J Med Sci 321: 215-224, 2001.
2. Beckman JS and Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol Cell Physiol 271: C1424-C1437, 1996.
3. Calabro P, Samudio I, Willerson JT, and Yeh ET. Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation 110: 3335-3340, 2004.
4. Gokce N, Vita JA, McDonnell M, Forse AR, Istfan N, Stoeckl M, Lipinska I, Keaney JF Jr, and Apovian CM. Effect of medical and surgical weight loss on endothelial vasomotor function in obese patients. Am J Cardiol 95: 266-268, 2005.
5. Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol 81: 18B-25B, 1998.
6. Grundy SM. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation 105: 2696-2698, 2002.
7. Knudson JD, Dincer UD, Dick GM, Shibata H, Akahane R, Saito M, and Tune JD. Leptin resistance extends to the coronary vasculature in prediabetic dogs and provides a protective adaptation against endothelial dysfunction. Am J Physiol Heart Circ Physiol 289: H1038-H1046, 2005.
8. Knudson JD, Dincer UD, Zhang C, Swafford AN Jr, Koshida R, Picchi A, Focardi M, Dick GM, and Tune JD. Leptin receptors are expressed in coronary arteries, and hyperleptinemia causes significant coronary endothelial dysfunction. Am J Physiol Heart Circ Physiol 289: H48-H56, 2005.
9. Kougias P, Chai H, Lin PH, Lumsden AB, Yao Q, and Chen C. Adipocyte-derived cytokine resistin causes endothelial dysfunction of porcine coronary arteries. J Vasc Surg 41: 691-698, 2005.
10. Lau DC, Dhillon B, Yan H, Szmitko PE, and Verma S. Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol 288: H2031-H2041, 2005.
11. Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, Seip R, Orlova C, and Mantzoros CS. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 88: 4848-4856, 2003.
12. Liu S, Beckman JS, and Ku DD. Peroxynitrite, a product of superoxide and nitric oxide, produces coronary vasorelaxation in dogs. J Pharmacol Exp Ther 268: 1114-1121, 1994.
13. Lyon CJ, Law RE, and Hsueh WA. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 144: 2195-2200, 2003.
14. McGill HC Jr, McMahan CA, Herderick EE, Zieske AW, Malcom GT, Tracy RE, and Strong JP. Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation 105: 2712-2718, 2002.
15. McTernan PG, Fisher FM, Valsamakis G, Chetty R, Harte A, McTernan CL, Clark PM, Smith SA, Barnett AH, and Kumar S. Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J Clin Endocrinol Metab 88: 6098-6106, 2003.
16. Miller FJ Jr, Gutterman DD, Rios CD, Heistad DD, and Davidson BL. Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis. Circ Res 82: 1298-1305, 1998.
17. Nishikawa Y, Stepp DW, and Chilian WM. Nitric oxide exerts feedback inhibition on EDHF-induced coronary arteriolar dilation in vivo. Am J Physiol Heart Circ Physiol 279: H459-H465, 2000.
18. Pfutzner A, Langenfeld M, Kunt T, Lobig M, and Forst T. Evaluation of human resistin assays with serum from patients with type 2 diabetes and different degrees of insulin resistance. Clin Lab 49: 571-576, 2003.
19. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, and Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111: 932-939, 2005.
20. Stocker R and Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev 84: 1381-1478, 2004.
21. Verma S, Li SH, Wang CH, Fedak PW, Li RK, Weisel RD, and Mickle DA. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 108: 736-740, 2003.
22. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, and Vinten-Johansen J. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 285: H579-H588, 2003.